145 related articles for article (PubMed ID: 35318646)
1. Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib.
Fischer K; Aringer M; Steininger J; Heil J; Beissert S; Abraham S; Günther C
Br J Dermatol; 2022 Sep; 187(3):432-435. PubMed ID: 35318646
[No Abstract] [Full Text] [Related]
2. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
Kim H; Dill S; O'Brien M; Vian L; Li X; Manukyan M; Jain M; Adeojo LW; George J; Perez M; Grom AA; Sutter M; Feldman BM; Yao L; Millwood M; Brundidge A; Pichard DC; Cowen EW; Shi Y; Lu S; Tsai WL; Gadina M; Rider LG; Colbert RA
Ann Rheum Dis; 2021 Mar; 80(3):406-408. PubMed ID: 32843325
[No Abstract] [Full Text] [Related]
3. Remission of anti-tumor necrosis factor-α antibody-induced palmoplantar pustulosis with the Janus kinase inhibitor baricitinib in a patient with rheumatoid arthritis.
Imafuku S; Maeyama A
J Dermatol; 2021 May; 48(5):e240-e241. PubMed ID: 33745215
[No Abstract] [Full Text] [Related]
4. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
[
